Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohan Khera

Showing results (271-280 of 276) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 276 results.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
JAMA|October 13, 2025
AI, Health, and Health Care Today and Tomorrow: The JAMA Summit Report on Artificial IntelligenceDerek C Angus, Rohan Khera, Tracy Lieu, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudyRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Pageof 28

Showing results (271-280 of 276) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 276 results.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
JAMA|October 13, 2025
AI, Health, and Health Care Today and Tomorrow: The JAMA Summit Report on Artificial IntelligenceDerek C Angus, Rohan Khera, Tracy Lieu, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudyRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Pageof 28